Monitoring immune responses in cancer patients receiving tumor vaccines

International Reviews of Immunology

Volumn 22, Issue 3-4, 2003, Pages 283-319

  Walker, Edwin B ^a   Disis, Mary L ^b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer vaccines; Immunomonitoring assays

Indexed keywords

CANCER VACCINE; CYTOKINE;

ACCURACY; ASSAY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNE SYSTEM; INTERMETHOD COMPARISON; PATIENT MONITORING; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; VALIDATION PROCESS;

CANCER VACCINES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0038274637     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180305226     Document Type: Review

References (135)

1. M. Bocchia, V. Bronte, M.P. Colombo, A. De Vincentiis, M. Di Nicola, G. Forni, L. Lanata, R.M. Lemoli, M. Massaia, D. Rondelli, P. Zanon, and S. Tura, Antitumor vaccination: Where we stand. Haematologica., 85(11): 1172-1206, 2000.
2. H. Hackstein, A.E. Morelli, and A.W. Thomson, Designer dendritic cells for tolerance induction: Guided not misguided missiles. Trends Immunol., 22(8): 437-442, 2001.
3. H. Jonuleit, E. Schmitt, K. Steinbrink, and A.H. Enk, Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol., 22(7): 394-400, 2001.
4. B. Pulendran, J. Banchereau, E. Maraskovsky, and C. Maliszewski, Modulating the immune response with dendritic cells and their growth factors. Trends Immunol., 22(1): 41-47, 2001.
5. M.K. Gately, L.M. Renzetti, J. Magram, A.S. Stern, L. Adorini, U. Gubler, and D.H. Presky, The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Ann. Rev. Immunol., 16: 495-521, 1998.
6. T.A. Waldmann, S. Dubois, and Y. Tagaya, Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity, 14(2): 105-110, 2001.
7. M.M. Davis, J.J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien, Ligand recognition by alpha beta T cell receptors. Ann. Rev. Immunol., 16: 523-544, 1998.
8. I.S. Grewal, and R.A. Flavell, CD40 and CD154 in cell-mediated immunity. Ann. Rev. Immunol., 16: 111-135, 1998.
9. A.D. Weinberg, A.T. Vella, and M. Croft, OX-40: Life beyond the effector T cell stage. Semin. Immunol., 10(6): 471-480, 1998.
10. C.A. Chambers, The expanding world of co-stimulation: The two-signal model revisited. Trends Immunol., 22(4): 217-223, 2001.
11. E.J. Fuchs, and P. Matzinger, Is cancer dangerous to the immune system? Semin. Immunol., 8(5): 271-280, 1996.
12. R. Medzhitov and C. Janeway, Jr., Innate immune recognition: Mechanisms and pathways. Immunol. Rev., 173: 89-97, 2000.
13. M.J. Smyth, D.I. Godfrey, and J.A. Trapani, A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol., 2(4): 293-299, 2001.
14. S. Sakaguchi, Regulatory T cells: Key controllers of immunologic self-tolerance. Cell., 101(5): 455-458, 2000.
15. M.J. Smyth and D.I. Godfrey, NKT cells and tumor immunity - A double-edged sword. Nat. Immunol., 1(6): 459-460, 2000.
16. P. Romero, M.J. Pittet, D. Valmori, D.E. Speiser, V. Cerundolo, D. Lienard, F. Lejeune, and J.C. Cerottini, Immune monitoring in cancer immunotherapy. Ernst Schering Res Found Workshop, 30: 75-97, 2000.
17. T.M. Clay, A.C. Hobeika, P.J. Mosca, H.K. Lyerly, and M.A. Morse, Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res., 7(5): 1127-1135, 2001.
18. E. Gilboa, Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol., 23(1): 101-107, 1996.
19. C.H. Chen and T.C. Wu, Experimental vaccine strategies for cancer immunotherapy. J. Biomed. Sci., 5(4): 231-252, 1998.
20. G. Pawelec, R.C. Rees, R. Kiessling, A. Madrigal, A. Dodi, C. Baxevanis, C. Gambacorti-Passerini, G. Masucci, and J. Zeuthen, Cells and cytokines in immunotherapy and gene therapy of cancer. Crit. Rev. Oncog., 10(1-2) 83-127, 1999.
21. M.R. Parkhurst, M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami, Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157(6): 2539-2548, 1996.
22. M.L. Salgaller, F.M. Marincola, J.N. Cormier, and S.A. Rosenberg, Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res., 56(20): 4749-4757, 1996.
23. M.B. Nielsen, and F.M. Marincola, Melanoma vaccines: The paradox of T cell activation without clinical response. Cancer Chemother. Pharmacol., 46(Suppl): S62-S66, 2000.
24. T.F. Gajewski, Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin. Diagn. Lab. Immunol., 7(2): 141-144, 2000.
25. G. Shankar and M.L. Salgaller, Immune monitoring of cancer patients undergoing experimental immunotherapy. Curr. Opin. Mol. Ther., 2(1): 66-73, 2000.
26. M.A. Morse, T.M. Clay, A.C. Hobeika, P.J. Mosca, and H.K. Lyerly, Monitoring cellular immune responses to cancer immunotherapy. Curr. Opin. Mol. Ther., 3(1): 45-52, 2001.
27. P.J. Mosca, A.C. Hobeika, T.M. Clay, M.A. Morse, and H.K. Lyerly, Direct detection of cellular immune responses to cancer vaccines. Surgery, 129(3): 248-254, 2001.
28. K. Kuzushima, Y. Hoshino, K. Fujii, N. Yokoyama, M. Fujita, T. Kiyono, H. Kimura, T. Morishima, Y. Morishima, and T. Tsurumi, Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry. Blood, 94(9): 3094-3100, 1999.
29. L.C. Tan, N. Gudgeon, N.E. Annels, P. Hansasuta, C.A. O'Callaghan, S. Rowland-Jones, A.J. McMichael, A.B. Rickinson, and M.F. Callan, A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol., 162(3): 1827-1835, 1999.
30. C.C. Czerkinsky, L.A. Nilsson, H. Nygren, O. Ouchterlony, and A. Tarkowski, A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods., 65(1-2): 109-121, 1983.
31. + T cells using an ELISPOT assay. J. Immunol. Methods, 181(1): 45-54, 1995.
32. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods, 191(2): 131-142, 1996.
33. T. Asai, W.J. Storkus, and T. L. Whiteside, Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol., 7(2): 145-154, 2000.
34. A. Schmittel, U. Keilholz, S. Bauer, U. Kuhne, S. Stevanovic, E. Thiel, and C. Scheibenbogen, Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J. Immunol. Methods, 247(1-2): 17-24, 2001.
35. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res., 3(2): 221-226, 1997.
36. C. Scheibenbogen, K.H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H.G. Rammensee, and U. Keilholz, Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int. J. Cancer., 71(6): 932-936, 1997.
37. J.G. Smith, X. Liu, R.M. Kaufhold, J. Clair, and M.J. Caulfield, Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol., 8(5): 871-879, 2001.
38. H.T. Maecker, H.S. Dunn, M.A. Suni, E. Khatamzas, C.J. Pitcher, T. Bunde, N. Persaud, W. Trigona, T.M. Fu, E. Sinclair, B.M. Bredt, J.M. McCune, V.C. Maino, F. Kern, and L.J. Picker, Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods, 255(1-2): 27-40, 2001.
39. J.M. Baust, B. Van, and J.G. Baust, Cell viability improves following inhibition of cryopreservation-induced apoptosis. In Vitro Cell Dev. Biol. Anim., 36(4): 262-270, 2000.
40. B. Feuerstein, T.G. Berger, C. Maczek, C. Roder, D. Schreiner, U. Hirsch, I. Haendle, W. Leisgang, A. Glaser, O. Kuss, T.L. Diepgen, G. Schuler, and B. Schuler-Thurner, A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods, 245(1-2): 15-29, 2000.
41. J. Schmidt-Mende, E. Hellstrom-Lindberg, B. Joseph, and B. Zhivotovsky, Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells. J. Immunol. Methods, 245(1-2): 91-94, 2000.
42. J.M. Baust, M.J. Vogel, R. Van Buskirk, and J.G. Baust, A molecular basis of cryopreservation failure and its modulation to improve cell survival. Cell Transplant., 10(7): 561-571, 2001.
43. T. Fu, D. Guo, X. Huang, M.R. O'Gorman, L. Huang, S.E. Crawford, and H.E. Soriano, Apoptosis occurs in isolated and banked primary mouse hepatocytes. Cell Transplant., 10(11): 59-66, 2001.
44. P.K. Lund, A.B. Westvik, G.B. Joo, R. Ovstebo, K.B. Haug, and P. Kierulf, Flow cytometric evaluation of apoptosis, necrosis and recovery when culturing monocytes. J. Immunol. Methods, 252(1-2): 45-55, 2001.
45. T. Yagi, J.A. Hardin, Y.M. Valenzuela, H. Miyoshi, G.J. Gores, and S.L. Nyberg, Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology, 33(6): 1432-1440, 2001.
46. P. Marrack, J. Kappler, and T. Mitchell, Type I interferons keep activated T cells alive. J. Exp. Med., 189(3): 521-530, 1999.
47. J. Sprent, X. Zhang, S. Sun, and D. Tough, T-cell proliferation in vivo and the role of cytokines. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 355(1395): 317-322, 2000.
48. + T cell responsiveness to antigen. J. Immunol., 161(5): 2141-2150, 1998.
49. A. T. Vella, S. Dow, T.A. Potter, J. Kappler, and P. Marrack, Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 95(7): 3810-3815, 1998.
50. + T cells in vivo by IL-15. Immunity, 8(5): 591-599, 1998.
51. X.C. Li, G. Demirci, S. Ferrari-Lacraz, C. Groves, A. Coyle, T.R. Malek, and T.B. Strom, IL-15 and IL-2: A matter of life and death for T cells in vivo. Nat. Med., 7(1): 114-118, 2001.
52. S. Yada, H. Nukina, K. Kishihara, N. Takamura, H. Yoshida, K. Inagaki-Ohara, K. Nomoto, and T. Lin, IL-7 prevents both caspase-dependent and -independent pathways that lead to the spontaneous apoptosis of i-IEL. Cell Immunol., 208(2): 88-95, 2001.
53. A. Vella, T.K. Teague, J. Ihle, J. Kappler, and P. Marrack, Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: Stat6 is probably not required for the effect of IL-4. J. Exp. Med., 186(2): 325-330, 1997.
54. + memory T cells by opposing cytokines. Science, 288(5466): 675-678, 2000.
55. J.S. Kuniyoshi, C.J. Kuniyoshi, A.M. Lim, F.Y. Wang, E.R. Bade, R. Lau, E.K. Thomas, and J.S. Weber, Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol., 193(1): 48-58, 1999.
56. G. Pirtskhalaishvili, G.V. Shurin, C. Esche, Q. Cai, R.R. Salup, S.N. Bykovskaia, M.T. Lotze, and M.R. Shurin, Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. British Journal of Cancer, 83(4): 506-513, 2000.
57. H.A. Pass, S.L. Schwarz, J.R. Wunderlich, and S.A. Rosenberg, Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am., 4(5): 316-323, 1998.
58. J.S. Weber, F.L. Hua, L. Spears, V. Marty, C. Kuniyoshi, and E. Celis, A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother., 22(5): 431-440, 1999.
59. C. Scheibenbogen, A. Schmittel, U. Keilholz, T. Allgauer, U. Hofmann, R. Max, E. Thiel, and D. Schadendorf, Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother., 23(2): 275-281, 2000.
60. M. Griffioen, M. Borghi, P.I. Schrier, and S. Osanto, Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int. J. Cancer., 93(4): 549-555, 2001.
61. + T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int. J. Cancer., 72(6): 972-976, 1997.
62. J. Banchereau, A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman, and J. Fay, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 61(17): 6451-6458, 2001.
63. H. Horig, D.S. Lee, W. Conkright, J. Divito, H. Hasson, M. LaMare, A. Rivera, D. Park, J. Tine, K. Guito, K.W. Tsang, J. Schlom, and H.L. Kaufman, Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother., 49(9): 504-514, 2000.
64. J.L. Marshall, R.J. Hoyer, M.A. Toomey, K. Faraguna, P. Chang, E. Richmond, J.E. Pedicano, E. Gehan, R.A. Peck, P. Arlen, K.Y. Tsang, and J. Schlom, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol., 18(23): 3964-3973, 2000.
65. A.H. Enk, T. Wolfel, and J. Knop, Decreased rate of progression and induction of tumor-specific immune response by adjuvant immunotherapy in stage IV melanoma. Hautarzt., 50(2): 103-108, 1999.
66. M.J. Pittet, D. Valmori, P.R. Dunbar, D.E. Speiser, D. Lienard, F. Lejeune, K. Fleischhauer, V. Cerundolo, J.C. Cerottini, and P. Romero, High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190(5): 705-715, 1999.
67. V. Rubio-Godoy, V. Dutoit, D. Rimoldi, D. Lienard, F. Lejeune, D. Speiser, P. Guillaume, J.C. Cerottini, P. Romero, and D. Valmori, Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc. Natl. Acad. Sci. USA., 98(18): 10302-10357, 2001.
68. A.M. Asemissen, D. Nagorsen, U. Keilholz, A. Letsch, A. Schmittel, E. Thiel, and C. Scheibenbogen, Flow cytometric determination of intracellular or secreted IFN-gamma for the quantification of antigen reactive T cells. J. Immunol. Methods, 251(2): 101-108, 2001.
69. Y. Okamoto, T. Abe, T. Niwa, S. Mizuhashi, and M. Nishida, Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T helper type 1- and T helper type 2-cells. Immunopharmacology, 39(2): 107-116, 1998.
70. M.D. Hesse, A.Y. Karulin, B.O. Boehm, P.V. Lehmann, and M. Tary-Lehmann, AT cell clone's avidity is a function of its activation state. J. Immunol., 167(3): 1353-1361, 2001.
71. L.J. Picker, M.K. Singh, Z. Zdraveski, J.R. Treer, S.L. Waldrop, P.R. Bergstresser, and V.C. Maino, Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood, 86: 1408, 1995.
72. M.A. Suni, L.J. Picker, and V.C. Maino, Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. Journal of Immunological Methods, 212: 89, 1998.
73. H. Asanuma, M. Sharp, H.T. Maecker, V.C. Maino, and A.M. Arvin, Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J. Infect. Dis., 181(3): 859-866, 2000.
74. + T cell cross-priming with exogenous antigens. J. Immunol., 166(12): 7268-7275, 2001.
75. F. Kern, I.P. Surel, C. Brock, B. Freistedt, H. Radtke, A. Scheffold, R. Blasczyk, P. Reinke, J. Schneider-Mergener, A. Radbruch, P. Walden, and H.D. Volk, T-cell epitope mapping by flow cytometry. Nat. Med., 4(8): 975-978, 1998.
76. A.J. Zajac, J.N. Blattman, K. Murali-Krishna, D.J. Sourdive, M. Suresh, J.D. Altman, and R. Ahmed, Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med., 188(12): 2205-2213, 1998.
77. F. Kern, I.P. Surel, N. Faulhaber, C. Frommel, J. Schneider-Mergener, C. Schonemann, P. Reinke, and H.D. Volk, Target structures of the CD8(+)-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited. J. Virol., 73(10): 8179-8184, 1999.
78. K.H. Lee, E. Wang, M.B. Nielsen, J. Wunderlich, S. Migueles, M. Connors, S.M. Steinberg, S.A. Rosenberg, and F.M. Marincola, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163(11): 6292-6300, 1999.
79. F. Kern, N. Faulhaber, C. Frommel, E. Khatamzas, S. Prosch, C. Schonemann, I. Kretzschmar, R. Volkmer-Engert, H.D. Volk, and P. Reinke, Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol., 30(6): 1676-1682, 2000.
80. + memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J. Immunol., 161(10): 5284-5295, 1998.
81. L.E. Nomura, J.M. Walker, and H.T. Maecker, Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry, 40(1): 60-68, 2000.
82. + memory T cell response to cytomegalovirus. J. Immunol., 167(3): 1151-1163, 2001.
83. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med., 5(5): 518-525, 1999.
84. V. Appay, D.F. Nixon, S.M. Donahoe, G.M. Gillespie, T. Dong, A. King, G.S. Ogg, H.M. Spiegel, C. Conlon, C.A. Spina, D.V. Havlir, D.D. Richman, A. Waters, P. Easterbrook, A.J. McMichael, and S.L Rowland-Jones, HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192(1): 63-75, 2000.
85. + T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res. Hum. Retroviruses, 16(18): 2065-2066, 2000.
86. M.A. Suni, S.A. Ghanekar, D.W. Houck, H.T. Maecker, S.B. Wormsley, L.J. Picker, R.B. Moss, and VC. Maino, CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur. J. Immunol., 31(8): 2512-2520, 2001.
87. S.A. Ghanekar, L.E. Nomura, M.A. Suni, L.J. Picker, H.T. Maecker, and V.C. Maino, Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin. Diagn. Lab. Immunol., 8(3):628-631, 2001.
88. + T-cell responses to CMV in HIV-1-infected subjects. Virology, 279(2): 459-470, 2001.
89. D. van Baarle, E. Hovenkamp, M.F. Callan, K.C. Wolthers, S. Kostense, L.C. Tan, H.G. Niesters, A.D. Osterhaus, A.J. McMichael, M.H. van Oers, and F. Miedema, Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood, 98(1): 146-155, 2001.
90. F. Lechner, D.K. Wong, P.R. Dunbar, R. Chapman, R.T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B.D. Walker, Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med., 191(9): 1499-1512, 2000.
91. P.A. Tilley, and J.N. Menon, Detection of mycobacterium-specific interferon-gamma-producing human T lymphocytes by flow cytometry. Apmis., 108(1): 57-66, 2000.
92. U. Kumaraguru, and B.T. Rouse, Application of the intracellular gamma interferon assay to recalculate the potency of CD8(+) T-cell responses to herpes simplex virus. J. Virol., 74(12): 5709-11, 2000.
93. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med., 4(8): 953-956, 1998.
94. + T cell counts and recurrent retinitis. J. Infect. Dis., 183(8): 1285-1289, 2001.
95. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, M. Roederer, and M.M. Davis, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5(6): 677-685, 1999.
96. V. Karanikas, J. Lodding, V.C. Maino, and I.F. McKenzie, Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res., 6(3): 829-8372 2000.
97. H.T. Maecker, S. Auffermann-Gretzinger, L.E. Nomura, A. Liso, D.K. Czerwinski, and R. Levy, Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res., 7(3 Suppl): 902s-908s, 2001.
98. A. Maraveyas, B. Baban, D. Kennard, G.A. Rook, M. Westby, J.M. Grange, P. Lydyard, J.L. Stanford, M. Jones, P. Selby, and A.G. Dalgleish, Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol., 10(7): 817-824, 1999.
99. S. Reinartz, H. Boerner, S. Koehler, A. Von Ruecker, H. Schlebusch, and U. Wagner, Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - A preliminary report. Hybridoma., 18(1): 41-45, 1999.
100. W.J. Moretto, L.A. Drohan, and D.F. Nixon, Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. Aids., 14(16): 2625-2627, 2000.
101. D.N. Garboczi, D.T. Hung, and D.C. Wiley, HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA., 89(8): 3429-3433, 1992.
102. J.D. Altman, P.A. Moss, P.J. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis, Phenotypic analysis of antigen-specific T lymphocytes. Science, 274(5284): 94-96, 1996.
103. W.W. Kwok, A.W. Liu, E.J. Novak, J.A. Gebe, R.A. Ettinger, G.T. Nepom, S.N. Reymond, and D.M. Koelle, HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: Direct detection of immunodominant antigen-responsive cells. J. Immunol., 164(8): 4244-4249, 2000.
104. A.L. Meyer, C. Trollmo, F. Crawford, P. Marrack, A.C. Steere, B.T. Huber, J. Kappler, and D.A. Hafler, Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl. Acad. Sci. USA., 97(21): 11433-11438, 2000.
105. E.J. Novak, S.A. Masewicz, A.W. Liu, A. Lernmark, W.W. Kwok, and G.T. Nepom, Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset. Int. Immunol., 13(6): 799-806, 2001.
106. J.A. Whelan, P.R. Dunbar, D.A. Price, M.A. Purbhoo, F. Lechner, G.S. Ogg, G. Griffiths, R.E. Phillips, V. Cerundolo, and A.K. Sewell, Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J. Immunol., 163(8): 4342-4348, 1999.
107. S.J. Youde, P.R. Dunbar, E.M. Evans, A.N. Fiander, L.K. Borysiewicz, V. Cerundolo, and S. Man, Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res., 60(2): 365-371, 2000.
108. L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G.A. Fisher, M.M. Davis, and E.G. Engleman, Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 98(15): 8809-8814, 2001.
109. M.A. Daniels, and S.C. Jameson, Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J. Exp. Med., 191(2): 335-346, 2000.
110. G. Denkberg, C.J. Cohen, and Y. Reiter, Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. J. Immunol., 167(1): 270-276, 2001.
111. G.S. Ogg, X. Jin, S. Bonhoeffer, P.R. Dunbar, M.A. Nowak, S. Monard, J.P. Segal, Y. Cao, S.L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D.D. Ho, D.F. Nixon, and A.J. McMichael, Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science, 279(5359): 2103-2106, 1998.
112. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol., 162(3): 1780-1788, 1999.
113. S.A. Kalams, P.J. Goulder, A.K. Shea, N.G. Jones, A.K. Trocha, G.S. Ogg, and B.D. Walker, Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol., 73(8): 6721-6728, 1999.
114. X.S. He, B. Rehermann, F.X. Lopez-Labrador, J. Boisvert, R. Cheung, J. Mumm, H. Wedemeyer, M. Berenguer, T.L. Wright, M.M. Davis, and H.B. Greenberg, Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA, 96(10): 5692-5697, 1999.
115. + T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol., 162(3): 1765-1771, 1999.
116. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med., 187(9): 1395-1402, 1998.
117. P.R. Dunbar, G.S. Ogg, J. Chen, N. Rust, P. van der Bruggen, and V. Cerundolo, Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol., 8(7): 413-416, 1998.
118. P. Romero, P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo, Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188(9): 1641-1650, 1998.
119. E. Ranieri, L.S. Kierstead, H. Zarour, J.M. Kirkwood, M.T. Lotze, T. Whiteside, and W.J. Storkus, Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunol. Invest., 29(2): 121-125, 2000.
120. H. Jonuleit, A. Giesecke-Tuettenberg, T. Tuting, B. Thurner-Schuler, T.B. Stuge, L. Paragnik, A. Kandemir, P.P. Lee, G. Schuler, J. Knop, and A.H. Enk, A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer, 93(2): 243-251, 2001.
121. P. Lee, F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, Gee, C., Lau, R., G.Jeffery, K. Margolin, V. Marty, and J. Weber, Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol., 19(18): 3836-3847, 2001.
122. V. Monsurro, M.B. Nielsen, A. Perez-Diez, M.E. Dudley, E. Wang, S.A. Rosenberg, and F.M. Marincola, Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol., 166(9): 5817-5825, 2001.
123. G. Yamshchikov, L. Thompson, W.G. Ross, H. Galavotti, W. Aquila, D. Deacon, J. Caldwell, J.W. Patterson, D.F. Hunt, and C.L. Slingluff, Jr., Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations. Clin. Cancer Res., 7(3 Suppl): 909s-916s, 2001.
124. + T cells after vaccination with antigenic peptide. Clin. Cancer Res., 7(3 Suppl): 796s-803s, 2001.
125. M.J. Pittet, A. Zippelius, D.E. Speiser, M. Assenmacher, P. Guillaume, D. Valmori, D. Lienard, F. Lejeune, J.C. Cerottini, and P. Romero, Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol., 166(12): 7634-7640, 2001.
126. J.J. Molldrem, P.P. Lee, C. Wang, R.E. Champlin, and M.M. Davis, A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res., 59(11): 2675-2681, 1999.
127. T.K. Hoffmann, V.S. Donnenberg, U. Friebe-Hoffmann, E.M. Meyer, C.R. Rinaldo, A.B. DeLeo, T.L. Whiteside, and A.D. Donnenberg, Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry, 41(4): 321-328, 2000.
128. + T cells in peripheral blood. Viral Immunol., 14(1): 59-69, 2001.
129. Y. Xiong, M.A. Luscher, J.D. Altman, M. Hulsey, H.L. Robinson, M. Ostrowski, B.H. Barber, and K.S. MacDonald, Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J. Virol., 75(6): 3028-3033, 2001.
130. + T cells comprise both naive and memory cells. J. Immunol., 162(12): 7080-7087, 1999.
131. +CD45RA+ pool with distinct phenotypic and migratory characteristics. J. Immunol., 167(1): 212-220, 2001.
132. R. Maile, B. Wang, W. Schooler, A. Meyer, E.J. Collins, and J.A. Frelinger, Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J. Immunol., 167(7): 3708-3714, 2001.
133. S.M. Anderton, C.G. Radu, P.A. Lowery, E.S. Ward, and D.C. Wraith, Negative selection during the peripheral immune response to antigen. J. Exp. Med. 193: 1-11, 2001.
134. U. Keilholz, J. Weber, J.H. Finke, D.I. Gabrilovich, W.M. Kast, M.L. Disis, J.M. Kirkwood, C. Scheibenbogen, J. Schlom, V.C. Maino, H.K. Lyerly, P.P. Lee, W. Storkus, F. Marincola, A. Worobee, and M.B. Atkins, Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society of Biological Therapy. J. Immuno. Ther. 25(2): 97-138, 2002.
135. P.G. Coulie, M. Somville, F. Lehmann, P. Hainaut, F. Brasseur, R. Devos, and T. Boon, Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer, 50(2): 289-297, 1992.